Medical Developments (ASX:MVP) share price hits new 52 week low

The Medical Developments share price is continuing to struggle today.

| More on:
laboratory workers looking disappointed

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price has fallen to a new 52-week low today.

The company hasn't released any news for nearly a fortnight. However, the last time the market heard from Medical Developments, it shared dire news.

Right now, the Medical Developments share price is $3.25, 2.99% lower than its previous close. It marks a new 12-month record low.

Additionally, Medical Developments was dropped from the S&P/ASX 300 Index (ASX: XKO) on Monday night.

Let's take a closer look at the latest from the specialised healthcare company.

Medical Developments struggles on the ASX

The last 2 weeks have been tough for the Medical Developments share price.

First off, the company released its earnings for financial year 2021 (FY21), sending its stock plummeting.

Medical Developments reported it had ended FY21 with a $12.6 million loss. For comparison, it reported a net profit after tax of $379,000 for FY20.

However, the company's revenue increased by 12.1% to 25.6 million in FY21.

Medical Developments also provided a promising outlook for FY22, stating it's looking forward to seeing strong sales growth for the year ending 30 June 2022.

Since the company released its FY21 results, Medical Development's shares have fallen 18.6%.

More recently, the company was dropped from S&P Dow Jones Indices' S&P/ASX 300 Index after Monday's close.

Following the company's removal from the index, Medical Developments' stock fell by 3% on Tuesday.

Medical Developments share price snapshot

Today's fall included, the Medical Developments share price has dropped more than half its value in 2021.

It is currently 51% lower than it was at the start of this year. It is also 41% lower than it was this time last year.

The company has a market capitalisation of around $233 million.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Medical Developments International Limited. The Motley Fool Australia owns shares of and has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

What does the Macquarie Hospital Claims Index mean for ASX 200 health insurance stocks?

Macquarie shares its view on Medibank Private and NIB Holdings.

Read more »

Two lab workers fist pump each other.
Broker Notes

What's JP Morgan's price target on CSL shares?

Are CSL shares undervalued or will they continue to underperform?

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

2 ASX healthcare stocks making huge moves on big news

These shares are getting investors excited today. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is up 15% on guidance upgrade?

Let's find out what is getting investors excited on Tuesday.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

3 reasons why the Sigma Healthcare share price could be a buy

This business has a very exciting outlook.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »